Loading clinical trials...
Loading clinical trials...
A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer
Conditions
Interventions
seliciclib
placebo
Locations
20
United States
Arizona Cancer Center
Tucson, Arizona, United States
Pacific Coast Hematology Oncology Group
Fountain Valley, California, United States
Pasco Hernando Oncology
New Port Richey, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
The University of Chicago
Chicago, Illinois, United States
University of Maryland, Greenebaun Cancer Center
Baltimore, Maryland, United States
Start Date
August 9, 2006
Primary Completion Date
March 3, 2009
Completion Date
April 7, 2009
Last Updated
December 22, 2021
NCT06043817
NCT07144280
NCT06758401
NCT07431827
NCT06427941
NCT06476808
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions